Document Detail


Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients.
MedLine Citation:
PMID:  9008250     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This multicenter, randomized, controlled clinical trial assessed the influence of sodium chloride intake on the antihypertensive effect of the calcium channel blocker isradipine. Participants with uncomplicated hypertension controlled by isradipine entered a 4-week sodium-restricted (60 to 80 mmol/24 h) period. Participants with urinary sodium levels < 120 mmol/24 h (n = 99) were randomized to placebo or sodium chloride (100 mmol/24 h) for 4 weeks, and then crossed over to the alternative treatment for an additional 4 weeks. Mean baseline systolic blood pressure was 151.9 +/- 16.7 mm Hg (mean +/- SD). During open-label isradipine treatment, systolic blood pressures for ad libitum sodium chloride and restriction were 134.1 +/- 11.1 and 132.1 +/- 12.2 mm Hg respectively; for double-blind sodium chloride restriction and supplementation: 133.6 +/- 12.6 and 138.5 +/- 12.8 mm Hg (P < .01). Urinary sodium excretion values for open-label isradipine ad libitum versus restricted were 140.6 +/- 61.9 versus 76.9 +/- 32.4 mmol/24 h; for double-blind restricted versus supplemented, sodium excretion was 120.5 +/- 68.9 v 175.9 +/- 68.7 mmol/24 h (P < or = .0001). Changes in urinary sodium excretion were not predictive of variations in blood pressure. Urinary sodium excretion during sodium restriction correlated directly with HDL-cholesterol (P < .02) and inversely with total cholesterol:HDL-cholesterol (P = .02), despite decreased total and saturated fat intake (P < .01). Sodium restriction was associated with significant reductions (P < .01) in virtually all macronutrients and electrolytes, and thus had an adverse impact on overall nutrition. The antihypertensive action of isradipine was not enhanced by dietary sodium chloride restriction, and the lipoprotein profile was least favorable with sodium chloride restriction.
Authors:
D A McCarron; A B Weder; B M Egan; G G Krishna; C D Morris; M Cohen; S Oparil
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  American journal of hypertension     Volume:  10     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  1997 Jan 
Date Detail:
Created Date:  1997-04-01     Completed Date:  1997-04-01     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  68-76     Citation Subset:  IM    
Affiliation:
Oregon Health Sciences University, Portland 97201, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antihypertensive Agents / administration & dosage*
Blood Pressure / drug effects*
Female
Humans
Hypertension* / drug therapy,  metabolism,  physiopathology
Isradipine / administration & dosage*
Male
Middle Aged
Sodium Chloride, Dietary / administration & dosage*
Grant Support
ID/Acronym/Agency:
DK40566/DK/NIDDK NIH HHS; M01-RR0042/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Sodium Chloride, Dietary; 75695-93-1/Isradipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A randomized study comparing a patient-directed hypertension management strategy with usual office-b...
Next Document:  Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, n...